Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066877 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL28614447 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL16923125 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL12487845 | 0.78 | LMNA (0.47) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29464261 | 0.78 | CYP19A1 (0.46) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL2658834 | 0.78 | CYP19A1 (0.46) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL13805938 | 0.78 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL31138265 | 0.78 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL8192197 | 0.74 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL13705859 | 0.74 | PDE10A (0.56) | CYP3A4CYP1A2CYP2D6CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-1164134-A1 | Benzimidazole compounds and their use as modulators of the GABA A receptor complex | NEUROSEARCH A/S (DK) | 2001-12-19 | — | — | EP | disclosed |
| EP-0821684-B1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2001-12-05 | — | — | EP | disclosed |
| US-5922724-A | Benzimidazole compounds and their use as modulators of the GABA a receptor complex | NEUROSEARCH A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| CN-1182427-A | Benzimidazole compounds and their use as modulators of GABA receptor complexes | NEUROSEARCH AS (DK) | 1998-05-20 | — | — | CN | disclosed |
| EP-0821684-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033194-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | CYP3A4 4562/4885CYP1A2 3484/4885CYP2D6 4316/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CYP3A4 4562/4885CYP1A2 3484/4885CYP2D6 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.